Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, Fissette L, David MP, Maréchal C, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Feldman RG, et al. Among authors: kostanyan l. Clin Infect Dis. 2024 Jan 25;78(1):202-209. doi: 10.1093/cid/ciad471. Clin Infect Dis. 2024. PMID: 37698366 Free PMC article.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. Among authors: kostanyan l. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Brandon D, Kimmel M, Kuriyakose SO, Kostanyan L, Mesaros N. Brandon D, et al. Among authors: kostanyan l. Vaccine. 2018 Oct 8;36(42):6325-6333. doi: 10.1016/j.vaccine.2018.08.051. Epub 2018 Sep 7. Vaccine. 2018. PMID: 30197282 Free article. Clinical Trial.
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M, Kostanyan L, Mesaros N, Kuriyakose S, Varman M. Kovac M, et al. Among authors: kostanyan l. Hum Vaccin Immunother. 2018;14(8):1977-1986. doi: 10.1080/21645515.2018.1460292. Epub 2018 May 10. Hum Vaccin Immunother. 2018. PMID: 29630439 Free PMC article. Clinical Trial.
Corrigendum to 'Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults'. [Vaccine 36 (2018) 6325-6333].
Brandon D, Kimmel M, Kuriyakose SO, Kostanyan L, Mesaros N. Brandon D, et al. Among authors: kostanyan l. Vaccine. 2020 Mar 10;38(12):2746-2747. doi: 10.1016/j.vaccine.2020.01.082. Epub 2020 Feb 13. Vaccine. 2020. PMID: 32061383 Free article. No abstract available.
Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Martinón-Torres F, Halperin SA, Nolan T, Tapiéro B, Perrett KP, de la Cueva IS, García-Sicilia J, Stranak Z, Vanderkooi OG, Kosina P, Rumlarova S, Virta M, Arribas JMM, Miranda-Valdivieso M, Novas BA, Bozensky J, Ortega MJC, Amador JTR, Baca M, Palomino EE, Zuccotti GV, Janota J, Marchisio PG, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Mesaros N. Martinón-Torres F, et al. Among authors: kostanyan l. Vaccine. 2021 Mar 12;39(11):1598-1608. doi: 10.1016/j.vaccine.2021.02.001. Epub 2021 Feb 19. Vaccine. 2021. PMID: 33612341 Free article. Clinical Trial.
Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Perrett KP, Halperin SA, Nolan T, Carmona Martínez A, Martinón-Torres F, García-Sicilia J, Virta M, Vanderkooi OG, Zuccotti GV, Manzoni P, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Stranak Z, Merino Arribas JM, Cilleruelo Ortega MJ, Miranda-Valdivieso M, Arias Novas B, Ramos Amador JT, Omeñaca F, Baca M, Marchisio PG, Mesaros N. Perrett KP, et al. Among authors: kostanyan l. Vaccine. 2020 Feb 18;38(8):2105-2114. doi: 10.1016/j.vaccine.2019.10.104. Epub 2019 Nov 24. Vaccine. 2020. PMID: 31776027 Free article. Clinical Trial.
Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.
Perrett KP, Halperin SA, Nolan T, Martínez Pancorbo C, Tapiero B, Martinón-Torres F, Stranak Z, Virta M, Vanderkooi OG, Kosina P, Encinas Pardilla MB, Cristobal García I, Zuccotti GV, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Marcos Fernández M, Rodríguez Zambrano MÁ, Martín García A, Asenjo de la Fuente JE, Camacho Marín MD, de la Calle Fernández-Miranda M, Romero Espinar Y, Marchisio PG, Manzoni P, Mesaros N. Perrett KP, et al. Among authors: kostanyan l. Vaccine. 2020 Feb 18;38(8):2095-2104. doi: 10.1016/j.vaccine.2019.10.105. Epub 2019 Nov 24. Vaccine. 2020. PMID: 31776029 Free article. Clinical Trial.
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, Hulstrøm V. Curran D, et al. Among authors: kostanyan l. Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb. Influenza Other Respir Viruses. 2024. PMID: 38314063 Free PMC article. Clinical Trial.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Among authors: kostanyan l. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. Clin Infect Dis. 2024. PMID: 38253338